1 citations
,
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.
March 2025 in “Journal of Drugs in Dermatology” A new method helps manage skin side effects from hormonal cancer therapy, improving patient care.
3 citations
,
December 2000 in “Journal of the Royal Society of Medicine” Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.
5 citations
,
January 2025 in “Cancers” Improving treatment plans can reduce hair loss and improve life quality for ovarian cancer patients.
4 citations
,
January 2011 in “International Journal of Clinical Medicine” Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
May 2023 in “Acta Oncologica” 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
November 2025 in “Revista Políticas Públicas & Cidades” Microagulhamento e intradermoterapia juntos melhoram o crescimento capilar em mulheres menopausadas.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
January 2004 in “Indian Journal of Nephrology”
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
1 citations
,
December 1971 in “PubMed” 14 citations
,
October 2015 in “Neurochemistry International” Letrozole may help prevent seizures by reducing certain hormone levels.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
March 2026 in “Journal of the American Academy of Dermatology”
36 citations
,
May 2017 in “The journal of sexual medicine” Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
1 citations
,
March 2011 in “Informa Healthcare eBooks” Hormonal therapy is effective for treating acne in adult women, especially with signs of high androgen levels.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
October 2024 in “Journal of the Endocrine Society” A rare ovarian tumor caused high testosterone in a postmenopausal woman, resolved by surgery.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
October 2024 in “Journal of the Endocrine Society” Bilateral salpingo-oophorectomy resolved hyperandrogenism in a postmenopausal woman with rare ovarian tumors.
12 citations
,
August 2020 in “Annals of Oncology” Androgen deprivation therapy might be better for preventing COVID-19 than treating it.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
12 citations
,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
78 citations
,
March 1989 in “The Journal of Clinical Endocrinology & Metabolism” High-dose androgen therapy can help manage certain types of androgen resistance.
April 2012 in “The Journal of Urology” Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.